BRPI1007318A2 - distribuição com liberação sustentada de um ou mais agentes. - Google Patents
distribuição com liberação sustentada de um ou mais agentes.Info
- Publication number
- BRPI1007318A2 BRPI1007318A2 BRPI1007318-3A BRPI1007318A BRPI1007318A2 BR PI1007318 A2 BRPI1007318 A2 BR PI1007318A2 BR PI1007318 A BRPI1007318 A BR PI1007318A BR PI1007318 A2 BRPI1007318 A2 BR PI1007318A2
- Authority
- BR
- Brazil
- Prior art keywords
- glaucoma
- agent
- core
- agents
- treatment
- Prior art date
Links
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 7
- 239000003795 chemical substances by application Substances 0.000 abstract 5
- 229940079593 drug Drugs 0.000 abstract 4
- 208000010412 Glaucoma Diseases 0.000 abstract 3
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 abstract 3
- 229960001160 latanoprost Drugs 0.000 abstract 3
- 229940124597 therapeutic agent Drugs 0.000 abstract 3
- 206010030043 Ocular hypertension Diseases 0.000 abstract 2
- 239000000030 antiglaucoma agent Substances 0.000 abstract 2
- 238000013270 controlled release Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004406 elevated intraocular pressure Effects 0.000 abstract 2
- 239000007943 implant Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 239000000607 artificial tear Substances 0.000 abstract 1
- 229960000686 benzalkonium chloride Drugs 0.000 abstract 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 239000003961 penetration enhancing agent Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229920001296 polysiloxane Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00772—Apparatus for restoration of tear ducts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
"distribuição com liberação sustentadade um ou mais agentes". os sistemas de distribuição por implante lacrimal e métodos aqui descritos fornecem a liberação controlada de um agente terapêutico para o tratamento de doenças, incluindo o tratamento do glaucoma, hipertensão ocular ou pressão intra-ocular elevada com latanoprost ou outros agentes anti-glaucoma. também é fornecido o tratamento de doenças, incluindo o tratamento do glaucoma, hipertensão ocular ou pressão intra-ocular elevada com latanoprost ou outros agentes anti-glaucoma em conjunto com um intensificador da penetração, tal como o cloreto de benzalcônio e/ou lágrimas artificiais. também são fornecidos implantes que contêm um núcleo de fármaco inserido em um ponto adjacente ao olho do paciente para a liberação controlada de um agente terapêutico, tal como latanoprost, para o tratamento do glaucoma, o núcleo de fármaco contendo um polímero tal como silicone reticulado, um agente terapêutico e um excipiente, em que o excipiente pode aumentar a taxa de liberação do agente do núcleo de fármaco ou pode aumentar o carregamento de fármaco no núcleo sem perda da homogeneidade desejável do agente dentro do núcleo ou pode aperfeiçoar a retenção do agente no olho ou no fluido lacrimal ou pode aumentar a penetração corneana do agente no olho.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14686009P | 2009-01-23 | 2009-01-23 | |
| US61/146,860 | 2009-01-23 | ||
| US15290909P | 2009-02-16 | 2009-02-16 | |
| US61/152,909 | 2009-02-16 | ||
| US22889409P | 2009-07-27 | 2009-07-27 | |
| US61/228,894 | 2009-07-27 | ||
| US27700009P | 2009-09-18 | 2009-09-18 | |
| US61/277,000 | 2009-09-18 | ||
| PCT/US2010/021868 WO2010085696A2 (en) | 2009-01-23 | 2010-01-22 | Sustained released delivery of one or more agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1007318A2 true BRPI1007318A2 (pt) | 2019-04-09 |
Family
ID=42356409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1007318-3A BRPI1007318A2 (pt) | 2009-01-23 | 2010-01-22 | distribuição com liberação sustentada de um ou mais agentes. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20100209477A1 (pt) |
| EP (1) | EP2389221B1 (pt) |
| JP (2) | JP5885244B2 (pt) |
| KR (1) | KR20110129869A (pt) |
| CN (2) | CN104306103B (pt) |
| AU (1) | AU2010206610A1 (pt) |
| BR (1) | BRPI1007318A2 (pt) |
| CA (1) | CA2750381C (pt) |
| CO (1) | CO6400201A2 (pt) |
| IL (1) | IL214199A0 (pt) |
| MX (1) | MX2011007804A (pt) |
| RU (1) | RU2011134043A (pt) |
| SG (1) | SG173069A1 (pt) |
| WO (1) | WO2010085696A2 (pt) |
| ZA (1) | ZA201105345B (pt) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2377569A1 (en) | 2004-07-02 | 2011-10-19 | QLT Plug Delivery, Inc. | Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device |
| CA2648421C (en) | 2006-03-31 | 2016-01-12 | Qlt Plug Delivery, Inc. | Nasolacrimal drainage system implants for drug therapy |
| CA2698580C (en) | 2007-09-07 | 2016-10-11 | Qlt Plug Delivery, Inc. | Lacrimal implant detection |
| JP5524841B2 (ja) | 2007-09-07 | 2014-06-18 | キュー エル ティー インク. | 涙管インプラント及び関連する方法 |
| NZ588938A (en) * | 2008-05-09 | 2013-03-28 | Mati Therapeutics Inc | Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
| US10238535B2 (en) * | 2009-02-23 | 2019-03-26 | Mati Therapeutics Inc. | Lacrimal implants and related methods |
| TWI495459B (zh) * | 2009-03-31 | 2015-08-11 | Johnson & Johnson Vision Care | 淚管塞(二) |
| US9421127B2 (en) | 2009-03-31 | 2016-08-23 | Johnson & Johnson Vision Care, Inc. | Punctal plugs |
| EP4108216A1 (en) | 2009-06-03 | 2022-12-28 | Forsight Vision5, Inc. | Anterior segment drug delivery |
| US20110105986A1 (en) * | 2009-09-21 | 2011-05-05 | Ben Bronstein | Uveoscleral drainage device |
| US9259351B2 (en) | 2010-03-29 | 2016-02-16 | Johnson & Johnson Vision Care, Inc. | Punctal plugs |
| US9259352B2 (en) | 2010-03-29 | 2016-02-16 | Johnson & Johnson Vision Care, Inc. | Punctal plugs |
| US10272040B2 (en) | 2010-08-12 | 2019-04-30 | Nanyang Technological University | Liposomal formulation for ocular drug delivery |
| US8591484B2 (en) | 2010-09-15 | 2013-11-26 | AlphaMed, Inc. | Lacrimal punctum measurement and occlusion |
| US8783451B2 (en) * | 2011-02-18 | 2014-07-22 | Allergan, Inc. | Unit dose breakable vial with integrated brush applicator |
| EP2701680B1 (en) | 2011-04-29 | 2018-10-31 | Allergan, Inc. | Sustained release latanoprost implant |
| EP3290024B1 (en) | 2011-08-29 | 2019-04-17 | Mati Therapeutics Inc. | Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
| US9974685B2 (en) | 2011-08-29 | 2018-05-22 | Mati Therapeutics | Drug delivery system and methods of treating open angle glaucoma and ocular hypertension |
| CN103917202B (zh) | 2011-09-14 | 2016-06-29 | 弗赛特影像5股份有限公司 | 眼插入件装置和方法 |
| US8834406B2 (en) * | 2011-10-21 | 2014-09-16 | Snyder Biomedical Corporation | Biocompatible glaucoma drainage device |
| CN104023760A (zh) | 2011-10-28 | 2014-09-03 | 普莱萨格生命科学公司 | 药物递送方法 |
| US20130220346A1 (en) * | 2012-02-28 | 2013-08-29 | Victor Lust | Balloon punctal plug |
| EP2844224B1 (en) * | 2012-05-03 | 2018-04-11 | Mati Therapeutics Inc. | Drug delivery system for treating open angle glaucoma and ocular hypertension |
| US9827250B2 (en) * | 2012-07-31 | 2017-11-28 | Johnson & Johnson Vision Care, Inc. | Lens incorporating myopia control optics and muscarinic agents |
| CN103767822A (zh) * | 2012-10-24 | 2014-05-07 | 鸿富锦精密工业(深圳)有限公司 | 辅助装置及利用该辅助装置进行眼药水投药的方法 |
| WO2014066775A1 (en) | 2012-10-26 | 2014-05-01 | Forsight Vision5, Inc. | Ophthalmic system for sustained release of drug to eye |
| US10993834B2 (en) | 2013-01-15 | 2021-05-04 | The Regents Of The University Of Colorado, A Body Corporate | Lacrimal system drug delivery device |
| CA2926515C (en) * | 2013-10-31 | 2020-11-24 | Allergan, Inc. | Prostamide-containing intraocular implants and methods of use thereof |
| US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
| WO2016168141A1 (en) | 2015-04-13 | 2016-10-20 | Forsight Vision5, Inc. | Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent |
| WO2017007819A1 (en) * | 2015-07-06 | 2017-01-12 | The Regents Of The University Of Colorado, A Body Corporate | Lacrimal drainage system diagnostic implant |
| JP6933377B2 (ja) * | 2015-07-21 | 2021-09-08 | アヴェドロ・インコーポレーテッドAvedro,Inc. | 光増感剤を用いた眼の処置用システム及び方法 |
| AU2016359288C1 (en) | 2015-11-23 | 2022-03-17 | The Regents Of The University Of Colorado, A Body Corporate | Lacrimal system for drug delivery |
| RU2613435C1 (ru) * | 2015-12-17 | 2017-03-16 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Дренаж для хирургического лечения глаукомы |
| JP7054211B2 (ja) | 2016-05-20 | 2022-04-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト | 涙腺ドラッグ送給デバイス |
| US11406532B2 (en) * | 2016-07-13 | 2022-08-09 | Mati Therapeutics Inc. | Static pin insertion tool for lacrimal implant |
| JP7088918B2 (ja) | 2016-09-30 | 2022-06-21 | マティ セラピューティクス,インク. | 眼薬徐放性製剤およびその利用 |
| US10603274B2 (en) * | 2016-09-30 | 2020-03-31 | Mati Therapeutics Inc. | Ophthalmic drug sustained release formulation and uses thereof |
| CN106963543A (zh) * | 2017-02-16 | 2017-07-21 | 武汉奥绿新生物科技股份有限公司 | 引流型柔性微型支架及医疗器械 |
| EP3746018B1 (en) * | 2018-02-02 | 2025-09-10 | Tusker Medical, Inc. | Systems and apparatus for transport and delivery of therapeutic substance to middle ear |
| US12268632B2 (en) * | 2018-05-12 | 2025-04-08 | Goldenbiotech, Llc | Self-retaining implantable drug delivery device |
| JP2021529747A (ja) * | 2018-06-25 | 2021-11-04 | タイタン ファーマシューティカルズ インコーポレイテッド | 親油性又は両親媒性医薬物質の放出のためのインプラント |
| US20220183880A1 (en) * | 2019-04-02 | 2022-06-16 | The Regents Of The University Of California | Method and apparatus to modify the cornea using electrochemistry |
| TWI819268B (zh) | 2020-01-16 | 2023-10-21 | 詹姆斯 W 希爾 | 藉由基因轉導改變眼睛顏色 |
| US11476105B2 (en) * | 2020-03-19 | 2022-10-18 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Concentric permeation system for transfer of neutral gaseous material |
| US20210338481A1 (en) * | 2020-04-20 | 2021-11-04 | Bruce B. Becker | Lacrimal gland implant for drug delivery and method |
| CA3177005A1 (en) * | 2020-04-27 | 2021-11-04 | Michael Goldstein | Methods of treating allergic conjunctivitis |
| US12396734B1 (en) * | 2020-09-10 | 2025-08-26 | Oasis Medical, Inc. | Devices and methods for occluding the punctal opening |
| WO2022182740A1 (en) | 2021-02-24 | 2022-09-01 | Ocular Therapeutix, Inc. | Intracanalicular depot inserter device |
| DE102021202061A1 (de) * | 2021-03-03 | 2022-09-08 | B. Braun Melsungen Aktiengesellschaft | Medizinprodukt, Funktionsteil für ein Medizinprodukt und Verfahren zum Sterilisieren und/oder zum Herstellen von Sterilisationsbeständigkeit eines Medizinprodukts oder Funktionsteils |
| EP4337143A4 (en) | 2021-05-14 | 2025-03-19 | Glaukos Corporation | MATERIALS AND METHODS FOR PUNCTURE PLUGS |
| WO2024097437A1 (en) * | 2022-11-03 | 2024-05-10 | Becker Bruce B | Anchored lacrimal caruncle implant for drug delivery and method |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4281654A (en) * | 1980-04-07 | 1981-08-04 | Alza Corporation | Drug delivery system for controlled ocular therapy |
| ES2078175B1 (es) * | 1993-12-31 | 1996-10-16 | Cusi Lab | Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones. |
| US6196993B1 (en) * | 1998-04-20 | 2001-03-06 | Eyelab Group, Llc | Ophthalmic insert and method for sustained release of medication to the eye |
| US6566345B2 (en) * | 2000-04-28 | 2003-05-20 | Fziomed, Inc. | Polyacid/polyalkylene oxide foams and gels and methods for their delivery |
| US6534693B2 (en) | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
| FR2834446B1 (fr) * | 2002-01-08 | 2004-02-13 | Ioltechnologie Production | Clou meatique a expansion |
| JP4262601B2 (ja) * | 2002-01-18 | 2009-05-13 | タカラバイオ株式会社 | 硫酸化フカン |
| US20040043067A1 (en) * | 2002-06-19 | 2004-03-04 | Salamone Joseph C. | Fluorosiloxane matrix controlled diffusion drug delivery systems |
| FR2844182B1 (fr) * | 2002-09-11 | 2004-12-03 | Humanoptics Ag | Bouchon d'obturation d'un canalicule lacrymal |
| US7785578B2 (en) * | 2002-10-11 | 2010-08-31 | Aciont, Inc. | Non-invasive ocular drug delivery |
| WO2004075781A2 (en) | 2003-02-26 | 2004-09-10 | Medivas, Llc | Bioactive stents and methods for use thereof |
| US7662864B2 (en) * | 2003-06-04 | 2010-02-16 | Rutgers, The State University Of New Jersey | Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent |
| US20050129731A1 (en) | 2003-11-03 | 2005-06-16 | Roland Horres | Biocompatible, biostable coating of medical surfaces |
| US20050232972A1 (en) * | 2004-04-15 | 2005-10-20 | Steven Odrich | Drug delivery via punctal plug |
| US7799336B2 (en) * | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US20060024350A1 (en) * | 2004-06-24 | 2006-02-02 | Varner Signe E | Biodegradable ocular devices, methods and systems |
| JP4412325B2 (ja) | 2004-08-27 | 2010-02-10 | 横浜ゴム株式会社 | 空気入りタイヤ用ランフラット支持体 |
| CA2648421C (en) * | 2006-03-31 | 2016-01-12 | Qlt Plug Delivery, Inc. | Nasolacrimal drainage system implants for drug therapy |
| US9173773B2 (en) * | 2006-06-21 | 2015-11-03 | Johnson & Johnson Vision Care, Inc. | Punctal plugs for the delivery of active agents |
| CN101505695A (zh) * | 2006-06-21 | 2009-08-12 | 庄臣及庄臣视力保护公司 | 用于递送活性试剂的泪点塞 |
| CN101505694B (zh) * | 2006-06-21 | 2012-02-22 | 庄臣及庄臣视力保护公司 | 用于递送活性试剂的泪点塞 |
| CA2674076A1 (en) * | 2006-12-26 | 2008-07-10 | Qlt Plug Delivery, Inc. | Drug delivery implants for inhibition of optical defects |
| UY30883A1 (es) * | 2007-01-31 | 2008-05-31 | Alcon Res | Tapones punctales y metodos de liberacion de agentes terapeuticos |
| US20080299176A1 (en) * | 2007-05-30 | 2008-12-04 | Yu-Chin Lai | Drug delivery device comprising crosslinked polyurethane-siloxane-containing copolymers |
| CN101327356A (zh) * | 2007-06-21 | 2008-12-24 | 庄臣及庄臣视力保护公司 | 用于输送活性剂的泪点塞 |
| CN101327357A (zh) * | 2007-06-21 | 2008-12-24 | 庄臣及庄臣视力保护公司 | 用于输送活性剂的泪点塞 |
| KR101696301B1 (ko) * | 2007-09-07 | 2017-01-13 | 마티 테라퓨틱스 인코포레이티드 | 치료 약제의 서방성 약물 코어 |
| CA2698580C (en) * | 2007-09-07 | 2016-10-11 | Qlt Plug Delivery, Inc. | Lacrimal implant detection |
| JP5524841B2 (ja) * | 2007-09-07 | 2014-06-18 | キュー エル ティー インク. | 涙管インプラント及び関連する方法 |
| MX2010002618A (es) * | 2007-09-07 | 2010-11-10 | Qlt Plug Delivery Inc | Herramientas de insercion y extraccion para implantes lagrimales. |
| CN102112076B (zh) * | 2007-09-07 | 2015-04-22 | 马缇医疗股份有限公司 | 泪腺植入物及相关方法 |
| CN102014816B (zh) * | 2008-02-18 | 2015-04-15 | 马缇医疗股份有限公司 | 泪管植入物及相关方法 |
| CN102105137B (zh) * | 2008-04-30 | 2015-01-07 | Qlt股份有限公司 | 复合泪管植入物及相关方法 |
| WO2010006053A1 (en) * | 2008-07-08 | 2010-01-14 | Qlt Plug Delivery, Inc. | Lacrimal implant body including comforting agent |
| EP2376019A1 (en) * | 2008-12-19 | 2011-10-19 | QLT, Inc. | Substance delivering punctum implants and methods |
| US10238535B2 (en) * | 2009-02-23 | 2019-03-26 | Mati Therapeutics Inc. | Lacrimal implants and related methods |
-
2010
- 2010-01-22 SG SG2011052487A patent/SG173069A1/en unknown
- 2010-01-22 WO PCT/US2010/021868 patent/WO2010085696A2/en not_active Ceased
- 2010-01-22 JP JP2011548154A patent/JP5885244B2/ja active Active
- 2010-01-22 KR KR1020117019322A patent/KR20110129869A/ko not_active Withdrawn
- 2010-01-22 CN CN201410551110.7A patent/CN104306103B/zh active Active
- 2010-01-22 CA CA2750381A patent/CA2750381C/en active Active
- 2010-01-22 US US12/692,452 patent/US20100209477A1/en not_active Abandoned
- 2010-01-22 RU RU2011134043/14A patent/RU2011134043A/ru not_active Application Discontinuation
- 2010-01-22 BR BRPI1007318-3A patent/BRPI1007318A2/pt not_active IP Right Cessation
- 2010-01-22 MX MX2011007804A patent/MX2011007804A/es unknown
- 2010-01-22 AU AU2010206610A patent/AU2010206610A1/en not_active Abandoned
- 2010-01-22 EP EP10733939.2A patent/EP2389221B1/en active Active
- 2010-01-22 CN CN201080009993.9A patent/CN102341144B/zh active Active
-
2011
- 2011-07-20 IL IL214199A patent/IL214199A0/en active IP Right Grant
- 2011-07-20 ZA ZA2011/05345A patent/ZA201105345B/en unknown
- 2011-08-01 CO CO11096469A patent/CO6400201A2/es not_active Application Discontinuation
-
2014
- 2014-08-25 US US14/468,262 patent/US20150064230A1/en not_active Abandoned
-
2015
- 2015-01-17 US US14/599,463 patent/US20150133546A1/en not_active Abandoned
-
2016
- 2016-02-04 JP JP2016019437A patent/JP2016127945A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2750381A1 (en) | 2010-07-29 |
| US20150133546A1 (en) | 2015-05-14 |
| CN104306103A (zh) | 2015-01-28 |
| CA2750381C (en) | 2021-03-16 |
| IL214199A0 (en) | 2011-08-31 |
| CO6400201A2 (es) | 2012-03-15 |
| CN102341144B (zh) | 2014-10-29 |
| EP2389221C0 (en) | 2023-08-16 |
| EP2389221B1 (en) | 2023-08-16 |
| JP2016127945A (ja) | 2016-07-14 |
| EP2389221A4 (en) | 2017-11-01 |
| CN104306103B (zh) | 2017-04-19 |
| US20100209477A1 (en) | 2010-08-19 |
| SG173069A1 (en) | 2011-08-29 |
| WO2010085696A3 (en) | 2010-11-04 |
| JP2012515628A (ja) | 2012-07-12 |
| ZA201105345B (en) | 2012-03-28 |
| US20150064230A1 (en) | 2015-03-05 |
| WO2010085696A9 (en) | 2011-06-03 |
| WO2010085696A2 (en) | 2010-07-29 |
| AU2010206610A1 (en) | 2011-08-11 |
| MX2011007804A (es) | 2011-12-06 |
| JP5885244B2 (ja) | 2016-03-15 |
| KR20110129869A (ko) | 2011-12-02 |
| RU2011134043A (ru) | 2013-02-20 |
| CN102341144A (zh) | 2012-02-01 |
| HK1162151A1 (en) | 2012-08-24 |
| EP2389221A2 (en) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1007318A2 (pt) | distribuição com liberação sustentada de um ou mais agentes. | |
| JP4685311B2 (ja) | 眼薬送出装置 | |
| KR100732262B1 (ko) | 약물 전달 장치 | |
| NZ588938A (en) | Sustained release delivery of active agents to treat glaucoma and ocular hypertension | |
| Bennett et al. | Material, immunological, and practical perspectives on eye drop formulation | |
| BRPI0510439A (pt) | implantes intraoculares de liberação sustentada contendo macromoléculas e métodos relacionados | |
| CA3010374A1 (en) | Intraocular pressure reduction with intracameral bimatoprost implants | |
| TW201012469A (en) | Combination treatment of glaucoma | |
| AU2014238174B2 (en) | Trans-sclera portal for delivery of therapeutic agents | |
| BRPI0510472A (pt) | implantes intra-oculares de liberação prolongada antiexcitotóxicos e métodos relacionados | |
| CN104856782A (zh) | 泪腺植入物及相关方法 | |
| US20150173951A1 (en) | Lacrimal filler | |
| Tighsazzadeh et al. | Matrix hyaluronic acid and bilayer poly-hydroxyethyl methacrylate-hyaluronic acid films as potential ocular drug delivery platforms | |
| Elvira et al. | Induced endothelial cell loss in phacoemulsification using topical anesthesia plus intracameral lidocaine | |
| Nagai et al. | A drug refillable device for transscleral sustained drug delivery to the retina | |
| Donnenfeld et al. | Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery | |
| MX2023009352A (es) | Metodos para la administracion oftalmica de roflumilast. | |
| Crnej et al. | A novel murine model for keratoprosthesis | |
| Tekko et al. | Microneedles for ocular drug delivery and targeting: challenges and opportunities | |
| Williams et al. | Ophthalmic biomaterials | |
| Gowda et al. | Therapeutic Applications of Nanobiomaterials for the Management of Ocular Diseases | |
| Meier-Gibbons et al. | Aqueous humor dynamics and its influence on glaucoma | |
| Keskin et al. | Ab interno approach of subconjunctival filtration with XEN gel stent | |
| Wang et al. | Accessing the suprachoroidal space for therapeutic delivery | |
| Vieira et al. | Xenographic lenticule implantation followed by riboflavin and UV treatment: A promising alternative for corneal ectasias management |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2519 DE 16-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |